Processa Pharmaceuticals (PCSA) Stock: Phase 2 Breast Cancer Update, 1-for-25 Reverse Split, and What Wall Street Is Watching on Dec. 18, 2025
December 18, 2025 — Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) is back on traders’ radar after the company reported fresh clinical observations from its Phase 2 breast cancer program and implemented another reverse stock split to consolidate shares. The result: a whiplash week for the stock, a surge in attention, and a new set of near-term catalysts that now matter more than anything else. Below is a detailed breakdown of the latest PCSA news, forecasts, and analysis circulating as of Dec. 18, 2025—and why the next clinical checkpoint in early 2026 is the real plot twist investors will be waiting for.
